Jackie Fairley, BSc, BVSc (Hons), MBA, GAICD, FTSE 
Chief Executive Officer

Dr Jackie Fairley has more than 30 years of operational experience in the pharmaceutical and biotechnology industries working in senior management roles with companies including CSL and Faulding/Hospira (now part of Pfizer). She was appointed Chief Executive Officer of Starpharma Holdings Ltd in July 2006. She holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from the University of Melbourne and was a practicing veterinary surgeon prior to joining CSL. Whilst at CSL she obtained an MBA from the Melbourne Business School where she was the recipient of the prestigious Clemenger Medal. Jackie is a non-executive director of the listed investment company Mirrabooka Investments Limited, is a member of the Invest Victoria Advisory Board (IVAB) and Carnegie Venture Capital’s investment Committee.  She has previously served on the Melbourne Business School Board, the Australian Federal Government’s Commonwealth Science Council and Pharmaceutical Industry Working Group and the Australian Federal Ministerial Biotechnology Advisory Council.


Tony Eglezos, BSc (Hons), PhD, MBA
Vice President, Business Development 

Dr Eglezos has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australasia. Most recently he was Director Commercial Operations, Pharmaceuticals, and In-Licensing at bioCSL and, prior to that, Senior Director Business Development and Licensing at CSL. During his 7 years in business development with CSL, Tony’s responsibilities included acquisitions and due-diligence, commercialisation of in-licensed pharmaceutical products and out-licensing of IP for partnered development for the global R&D group. Tony has a PhD in Immunology from the University of Melbourne and an MBA from the University of Technology Sydney.


David Owen, BSc (Hons), PhD 
Vice President, Research

Dr Owen has extensive experience in medicinal chemistry and biochemistry, and in managing teams focused on commercially directed drug discovery. He has held several positions in the biotech industry including Mimotopes, Cerylid and Glykoz and gathered extensive international experience in biotechnology and pharmaceutical research and development. Since joining Starpharma David has driven the drug delivery programs by developing and executing a number of successful proof-of-concept studies. The results from these studies have led to a number of commercial partnerships such as Stiefel a GSK company, Lilly, AstraZeneca, ChaseSun and Merck as well as driving Starpharma's own internal drug delivery program which has delivered 3 internal clinical candidates, currently in phase 2 clinical trials and one partnered candidate AZD0466 with AstraZeneca which is in a global phase 1/2 clinical trial.



Jeremy Paull, BSc (Hons), PhD
Vice President, Development and Regulatory Affairs

Dr Jeremy Paull has more than 20 years’ experience in pharmaceutical and medtech product development, regulatory affairs, and commercialisation.  Jeremy has managed all aspects of multiple development and commercialisation projects for products in areas including HIV/STIs, COVID-19, women’s health, dermatology, and oncology, and has achieved market approval and commercialisation of medical device and combination products in global markets. Jeremy has also advanced pharmaceutical products through late stage, global phase 3 clinical trials, and led engagement with global regulatory agencies (FDA, EMA, TGA, MHRA, PMDA). Jeremy leads a team of senior technical managers and was Principal Investigator for two concurrent US NIH-funded, multi-year, multi-million dollar research and product commercialisation programs involving collaborations with world-renowned, local and international academic institutions and commercial partners. He is a current member of AusBiotech’s AusMedtech Regulatory Affairs Expert Panel and past member of the AusMedtech Victoria Committee. Jeremy has been a member of the executive leadership team of Starpharma since 2003 and has completed executive leadership training at Kellogg School of Management at Northwestern University, Melbourne Business School, and Australian Graduate School of Management at UNSW. He joined Starpharma in 2001 from medtech company, Norwood Abbey, and has a PhD in pharmacology from Monash University.



Nigel Baade, BCom , CPA, Grad Dip Arts (Development)
Chief Financial Officer & Company Secretary 

The Company Secretary is Mr Nigel Baade, holding the position since 2013. Mr Baade also holds the position of Chief Financial Officer, which he has held since January 2009. Mr Baade is a Certified Practising Accountant (CPA) with extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Starpharma as Financial Controller in 2006, he has held positions at Hagemeyer, Cerylid Biosciences, Faulding (now Pfizer) and UMT (Fonterra). Mr Baade holds qualifications from University of Tasmania and Monash University.  Mr Baade is a former director of BioMelbourne Network Inc and served as its Treasurer and Chairman of the Finance, Audit and Risk Committee. Mr Baade is a member of the Australian Institute of Company Directors.


Filippa Shub, Registered Patent and Trademark Attorney, B.Sc (Biol), M.Sc (Prlm), GDip IP Law, MBA, FIPTA
Director of Intellectual Property

Ms Shub is a qualified Patent and Trademark Attorney with responsibility for managing the Intellectual Property assets of the Company. She has more than 20 years’ experience in Research, Commercialisation, and Intellectual Property. Before joining Starpharma Ms Shub worked with both legal firms and biotechnology companies in Australia and USA, including Davies, Collison Cave, Allens Arthur Robinson, Norwood Abbey and CSL.